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PURPOSE: To establish the Southern blotting technique using hybridization with a nonradioactive probe to detect
large rearrangements of CYP21A2 in a Brazilian cohort with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
(CAH-21OH).
METHOD: We studied 42 patients, 2 of them related, comprising 80 non-related alleles. DNA samples were obtained
from peripheral blood, digested by restriction enzyme Taq I, submitted to Southern blotting and hybridized with biotin-
labeled probes.
RESULTS: This method was shown to be reliable with results similar to the radioactive-labeling method. We found
CYP21A2 deletion (2.5%), large gene conversion (8.8%), CYP21AP deletion (3.8%), and CYP21A1P duplication (6.3%).
These frequencies were similar to those found in our previous study in which a large number of cases were studied. Good
hybridization patterns were achieved with a smaller amount of DNA (5 µg), and fragment signs were observed after 5 minutes
to 1 hour of exposure.
CONCLUSIONS: We established a non-radioactive (biotin) Southern blot/hybridization methodology for CYP21A2
large rearrangements with good results. Despite being more arduous, this technique is faster, requires a smaller amount of
DNA, and most importantly, avoids problems with the use of radioactivity.
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Congenital adrenal hyperplasia
(CAH) due to 21-hydroxylase defi-
ciency (21OHD) is one of the most fre-
quently inherited metabolism disor-
ders. The impairment of 21OH activ-
ity decreases cortisol synthesis, result-
ing in chronic stimulation of the adre-
nal cortex by adrenocorticotrophic
hormone with consequent adrenal hy-
perplasia, leading to accumulation of
steroid precursors, including andro-
gens, causing virilization.
Congenital adrenal hyperplasia due
to 21-hydroxylase deficiency is tradi-
tionally divided into classical and
non-classical forms. The classical form
is divided into salt-wasting (SW) and
simple virilizing (SV) forms.1 In the
classical form, virilization begins
prenatally and females present ambigu-
ous genitalia at birth, virilization con-
tinues postnatally in both sexes caus-
ing enlargement of the clitoris or pe-
nis, precocious pubarche and advance
of bone maturation resulting in re-
duced final height.2 In about two-
thirds of the cases, a severe mineralo-
corticoid deficiency develops, leading
to the inability to conserve urinary so-
dium (SW form) causing dehydration
with hyponatremia and hyperkalemia
at first weeks after birth.3 In the
nonclassical form (NC), symptoms of
androgen excess, such as precocious
pubarche, menstrual abnormalities,
acne, hirsutism, and infertility, when
present, appear during childhood, pu-
berty, or adult life. The different clini-
cal forms are due to different degrees
of enzyme activity caused by muta-
tions present in the gene that codifies
21-hydroxylase, the CYP21A2 gene.4
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The CYP21A2 gene and its
pseudogene CYP21A1P are located 30
kb from each other on the short arm of
chromosome 6 (6p21.3), within the lo-
cus that codifies the human leukocyte
antigen (HLA) complex class III, adja-
cent to and alternating with the C4A
and C4B genes, which encode the
fourth component of complement.
Both genes contain 10 exons and
present high homology (98% in the
exon sequences). The gene adjacent to
C4A is the pseudogene that has several
mutations and therefore does not pro-
duce a protein, and the gene adjacent
to C4B is the active gene that codifies
a protein with 494 amino acids.5,6
This region of chromosome 6 has
at least 5 pairs of duplicated genes
with high levels of nucleotide identity.
This homology predisposes unequal
pairing during meiosis, leading to un-
equal crossing-over between the active
gene and its pseudogene, causing de-
letions, duplications, and transference
of deleterious sequences from the
CYP21A1P gene to CYP21A2 (large
and microconversions).7,8
Usually, the large mutations are de-
tected by Southern blot techniques
followed by hybridization with a ra-
dioactive probe, while the point mu-
tations are studied by allele-specific
polymerase chain reaction (PCR),9,10
direct sequencing of PCR products,11
allele-specific hybridization (ASO),11-
14
 or ligase detection reactions.15,16 The
frequency of large mutations varies
from 11% to 33% of the alleles of in-
dividuals with CAH 21-OHD and oc-
curs mainly in the classical form in dif-
ferent populations.17-22
The Southern blot method nor-
mally requires the use of radioactive
material, usually 32P, to label probes.
The majority of the studies analyzing
large rearrangements in CAH 21-OHD
patients use this material.32P is highly
hazardous, and the laboratory needs a
license and trained personal to work
with this material.
Our aim was to establish the use of
nonradioactive labeling with the
Southern blot methodology, studying
42 patients with different clinical
forms of CAH-21-OHD.
Nonradioactive labeling has al-
ready been used in other studies with
other genes.23,24
PATIENTS
All families gave their informed
consent for the genetic study.
We studied 42 patients with CAH-
21OH, 5 genetically males and 37 fe-
males; 9 had the SV form, 11 had the
SW form, and 22 had the NC form.
These patients belong to 41 families,
2 of them related. One family reported
first-degree consanguinity and there
were 2 affected sons in another family.
The parents, when available, were also
studied in order to segregate the mu-
tations. Therefore, we studied 80 non-
related alleles, 16 of the SV form, 21
of the SW form, and 43 of the NC
form.
The SV form was diagnosed when
ambiguous genitalia was seen at birth
in females and isosexual precocious
puberty in males. In the SW form, in
addition to the virilization signals, the
patients also presented a history of
salt-wasting crises during the first
weeks of life. In the classical form, the
basal levels of 17-hydroxyproges-
terone were >60 ng/mL. The patients
with the NC form presented precocious
pubarche, primary or secondary
amenorrhea, hirsutism, and 17-
hydroxyprogesterone levels after
ACTH stimulation >10 ng/mL.25
METHODS
DNA samples from patients and
their relatives were obtained from pe-
ripheral blood by the proteinase K
phenol/chloroform method 26 and
stocked in TE 10:1 (Tris-HCl 10mM,
pH 7.5 ; EDTA 1mM pH 8.0) at 4°C.
Six micrograms of genomic DNA
was digested with the Taq I
(Invitrogen) restriction enzyme, with a
concentration of 5 µg DNA, according
to the manufacturer’s instructions. The
digested DNA was submitted to elec-
trophoresis for 36 hours at 40 V. After
36 hours, the DNA was transferred from
the gel to nylon membranes by capil-
larity using a 10x SSC solution (20x
SSC = 3M sodium chloride, 0.3M so-
dium citrate) and was fixed in the mem-
brane by incubation for 1 hour at
80°C.
The probes were labeled with bi-
otin-14-dCTP by random priming, us-
ing the manufacturer’s instructions
(Bioprime DNA Labeling Gibco-
BRL). In brief, 200 ng of probe to-
gether with a random primer solution
were denatured by boiling for 5 min-
utes and cooled in ice. A dNTP mix-
ture and 40 UI of Klenow enzyme were
added, and the solution was main-
tained at 37oC for 3 hours. After that,
the reaction was stopped and the un-
incorporated nucleotides were sepa-
rated from the probe through a
Sephadex G50 column.
Pre-hybridization, hybridization,
and detection of the labeled probe
were performed according to the manu-
facturer’s instructions. Pre-hybridiza-
tion and hybridization were performed
at 42oC in 5xSSPE, 0.1% Denhardt’s
solution, 5% dextran sulfate, 1% SDS,
0.2mg/mL denatured salmon sperm
DNA and 50% formamide solution.
The pre-hybridization was carried out
for 4 hours while hybridization took
24 hours. After hybridization, mem-
branes were submitted to stringent
washes (65oC and 50oC), and the
streptavidine-alkaline-phosphatase
conjugate was bonded to the hybrid-
ized biotinylated probe. The
chemiluminescent detection was done
with the Photogene Nucleic Acid De-
tection System version 2.0 kit (Gibco-
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BRL). The membrane was incubated
with an alkaline phosphatase substrate
(LUMI-PHOS) that emits light when
dephosphorylated and exposed to X-
ray films. This procedure was per-
formed to determine the number of
copies of CYP21 genes. The number of
copies of a fragment was determined
comparing the signal intensity of both
CYP21 genes in the same electro-
phoretic lane. The fragments of 3.7 and
2.5 kB correspond to the CYP21A2
gene and the fragments of 3.2 and 2.4
kB to the CYP21A1P gene. For a pre-
cise molecular diagnosis, as in the ra-
dioactive labeling methodology, a
densitometric analysis to compare the
intensity of the signal of the bands
would be necessary, although results
with and without densitometry were
very similar.
RESULTS
Hybridization patterns of the sam-
ples obtained with the biotinylated
probe are shown in Figure 1. The first
column shows the lack of the 3.7 kB
band and the presence of the 3.2, 2.5
and 2.4 kB bands with same intensity
of signal, indicating a homozygous
large gene conversion. The third and
fourteenth columns show a decreased
signal in the 3.2 and 2.4 kB bands
when compared respectively to the 3.7
and 2.5 kB bands, indicating a hetero-
zygous CYP21A1P deletion. In the
fourth column, there is a heterozygous
gene conversion because of decreased
signal of the 3.7 kB band compared to
the 3.2 kB, 2.4, and 2.5 kB bands with
same intensity of signal. The fifth to
twelfth columns represent normal hy-
bridization patterns. For a better under-
standing of the results, Figure 2 shows
the Taq I restriction sites in CYP21A2
and its pseudogene.
Figure 2 - Representation of Taq I restriction sites of CYP21A1P and CYP21A2 genes. Fragments of 3,2 and 2,4 kB are from the pseudogene
(CYP21A1P) and fragments of 3,7 and 2,5 kB are from the active gene (CYP21A2).
Figure 1 - Hybridization pattern of the biotinylated CYP21A2 probe to genomic DNA digested by Taq I restriction enzyme. Lane 1 homozygous
gene conversion; lanes 2 and 13, heterozygous CYP21A1P duplication; lanes 3 and 14, heterozygous CYP21A1P deletion; lane 4, heterozygous
gene conversion; lanes 5 to 12, normal hybridization pattern.
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Analyzing these 80 unrelated
alleles, we found that 78.6% of the
alleles presented a normal hybridiza-
tion pattern, 2.5% a CYP21A2 deletion
pattern, 8.8% a large gene conversion,
and 3.8% and 6.3% presented
CYP21A1P deletion and duplication
patterns, respectively. As expected, the
CYP21A2 deletion and the large gene
conversion occurred only in the SW
form, and the CYP21A1P duplication
was observed mainly in the non-clas-
sical form, CYP21A2 duplication was
not found.
DISCUSSION
The main purpose of this work was
establish in our service the screening of
large mutations with a non-
radiolabelling methodology, since ra-
dioactive reagents are harder to obtain,
have a short half life, are dangerous
when used by people who are not well
trained to handle them, and produce
hazardous waste materials that require
special facilities for long-term storage.
We observed that biotin labeling
emits a signal equivalent in intensity
to that of radioactive labeling. Another
advantage of this method is that due
to its greater sensitivity, smaller
amounts of DNA are needed (2 - 5 µg
compared to 10 µg when 32P is used).
Sometimes large amounts of DNA are
not available. The smaller amount of
DNA needed and the shorter time re-
quired for exposure to X-ray films
make this procedure more effective for
use in prenatal diagnosis of large gene
rearrangements in families with a his-
tory of CAH 21-OHD.
In this study we found a low inci-
dence of large rearrangements involv-
ing CYP21A2 in our sample (10.3% of
non-related-alleles). CYP21A2 dele-
tions were seen only in the SW form,
and large gene conversions were ob-
served in the NC (4.7%) and SW
(23.8%) forms. The CYP21A1P
rearrangements are not mutations caus-
ing disease but can be associated with
CYP21A2 point mutations. The fre-
quency of large rearrangement muta-
tions in this sample was similar to that
found in a previous population study
in a Brazilian sample performed by our
group with different patients compris-
ing a large number of cases.21 For com-
parison of both methodologies, some
of the patients included in this study
with biotin labeling had a previous
molecular diagnosis by a radiolabeling
methodology, with similar results.
In conclusion, the nonradioactive
(biotin) labeling, although more ardu-
ous, allowed accurate molecular diag-
nosis of large gene rearrangements in
patients with CAH 21-OHD with the
advantages of the use of a small
amount of DNA and avoiding the use
of hazardous radioactive material. This
technique proved to be a good alter-
native for routine use.
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RESUMO
CUKIER P e col. Uso de marcação não
radiativa para identificação de
grandes rearranjos gênicos na de-
ficiência da 21-hidroxilase. Rev.
Hosp. Clín. Fac. Med. S. Paulo
59(6):369-374, 2004.
OBJETIVO: Padronizar a técnica
de Southern blotting usando hibridi-
zação com material não radioativo
para detectar grandes rearranjos no
gene CYP21A2 em uma amostra da po-
pulação brasileira com hiperplasia
adrenal congênita.
MÉTODO: Foram estudados 42
pacientes, 2 dos quais aparentados,
totalizando 80 alelos não relaciona-
dos. As amostras de DNA foram obti-
das de sangue periférico, digeridas
com enzima de restrição Taq I, reali-
zado Southern blotting e hibridizadas
com sonda marcada com biotina.
RESULTADOS: O método se mos-
trou eficaz, com resultados similares
aos encontrados ao utilizar a metodo-
logia com material radioativo. Foram
encontradas 2,5% de deleção do
CYP21A2, 8,8% de grandes conver-
sões, 3,8% de deleção do CYP21A1P
e 6,3% de duplicação do CYP21A1P.
Estas freqüências foram similares às
encontradas em nosso estudo prévio,
onde um número significante de casos
foi estudado. Um bom padrão de
hibridização foi alcançado utilizando
menor quantidade de DNA (5mg) e a
emissão de sinais foi observada entre
5 minutos e 1 hora de exposição.
CONCLUSÕES: Padronizamos
uma técnica de Southern blotting/
hibridização com material não radioa-
tivo (biotina) para a pesquisa de gran-
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des rearranjos no gene CYP21A2 com
bons resultados. Apesar de ser mais tra-
balhoso, este método é mais rápido,
utiliza menores quantidades de DNA
e, principalmente, evita problemas com
o uso de radioatividade.
UNITERMOS: Biotina. Grandes
rearranjos. Southern blotting. CAH-
21OH.
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